IL-23 in axial spondyloarthritis and psoriatic arthritis: a good fit for biological treatment?

References

• Tang C, Chen S, Qian H, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012 Feb;135(2):24–112.
   Web of Science ®Google Scholar
• Kleinschek MA, Muller U, Brodie SJ, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol. 2006 Jan 15 176(2):1098–1106.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov;13(5):715–725.
   PubMed Web of Science ®Google Scholar
• McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2006 Jan;27(1):17–23.
   PubMed Web of Science ®Google Scholar
• Goldberg M, Nadiv O, Luknar-Gabor N, et al. Synergism between tumor necrosis factor alpha and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol. 2009 May;46(8–9):1854–1859.
   PubMed Web of Science ®Google Scholar
• Brentano F, Ospelt C, Stanczyk J, et al. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann Rheum Dis. 2009 Jan;68(1):143–150.
   PubMed Web of Science ®Google Scholar
• Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology. 2009 Feb;126(2):85–177.
   Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003 Feb 13 421(6924):744–748.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005 Jan 17 201(2):233–240.
   PubMed Web of Science ®Google Scholar
• Kopp T, Lenz P, Bello-Fernandez C, et al. IL-23 production by cosecretion of endogenous p19 and transgenic p40 in keratin 14/p40 transgenic mice: evidence for enhanced cutaneous immunity. J Immunol. 2003 Jun 01;170(11):44–5438.
   Web of Science ®Google Scholar
• Belladonna ML, Renauld JC, Bianchi R, et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol. 2002 Jun 01 168(11):5448–5454.
   PubMed Web of Science ®Google Scholar
• Bastos KR, de Deus Vieira de Moraes L, Zago CA, et al. Analysis of the activation profile of dendritic cells derived from the bone marrow of interleukin-12/interleukin-23-deficient mice. Immunology. 2005 Apr;114(4):499–506.
   PubMed Web of Science ®Google Scholar
• Petermann F, Rothhammer V, Claussen MC, et al. γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity. 2010 Sep 24 33(3):351–363.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003 Jan 17 278(3):1910–1914.
   PubMed Web of Science ®Google Scholar
• Awasthi A, Riol-Blanco L, Jäger A, et al. Cutting edge: IL-23 receptor gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol. 2009 May 15 182(10):5904–5908.
   PubMed Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007 Jul 26 448(7152):480–483.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007 Sep;8(9):967–974.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006 May 11 441(7090):235–238.
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006 Feb;24(2):179–189.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007 Dec;8(12):1390–1397.
   PubMed Web of Science ®Google Scholar
• Mangan PR, Harrington LE, O’Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006 May 11 441(7090):231–234.
   PubMed Web of Science ®Google Scholar
• Chen Z, Tato CM, Muul L, et al. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007 Sep;56(9):2936–2946.
   PubMedGoogle Scholar
• Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007 Sep;8(9):7–950.
   Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007 Sep;8(9):942–949.
   PubMed Web of Science ®Google Scholar
• Morishima N, Mizoguchi I, Takeda K, et al. TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem Biophys Res Commun. 2009 Aug 14 386(1):105–110.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007 Jul 26 448(7152):484–487.
   PubMed Web of Science ®Google Scholar
• Huber M, Brüstle A, Reinhard K, et al. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci U S A. 2008 Dec 30 105(52):20846–20851.
   PubMed Web of Science ®Google Scholar
• Wei L, Laurence A, Elias KM, et al. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 2007 Nov 30 282(48):34605–34610.
   PubMed Web of Science ®Google Scholar
• Ivanov ZL II, Littman DR, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol. 2007 Dec;19(6):409–417.
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Jain R, Garg AV, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014 Sep;14(9):585–600.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017 Mar 9; 376(10):957–970.
   PubMed Web of Science ®Google Scholar
• Schön MP, Boehncke, Boehncke. Psoriasis. N Engl J Med. 2005 May 05; 352(18):1899–1912.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007 Feb 22; 445(7130):866–873.
   PubMed Web of Science ®Google Scholar
• Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018 Jun 02;391(10136):84–2273.
   Web of Science ®Google Scholar
• Stuart PE, Nair RP, Tsoi LC, et al. Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015 Dec 03 97(6):816–836.
   PubMed Web of Science ®Google Scholar
• Hüffmeier U, Uebe S, Ekici AB, et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet. 2010 Nov;42(11):996–999.
   PubMed Web of Science ®Google Scholar
• Bowes J, Budu-Aggrey A, Huffmeier U, et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat Commun. 2015 Feb 05;6:6046.
   PubMed Web of Science ®Google Scholar
• Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012 Jul;18(7):1069–1076.
   PubMed Web of Science ®Google Scholar
• Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015 Oct;11(10):562.
   PubMed Web of Science ®Google Scholar
• Bettelli E, Korn T, Oukka M, et al. Induction and effector functions of T(H)17 cells. Nature. 2008 Jun 19 453(7198):1051–1057.
   PubMed Web of Science ®Google Scholar
• Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003 Dec;198(12):1951–1957.
   PubMed Web of Science ®Google Scholar
• Chen L, Wei XQ, Evans B, et al. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol. 2008 Oct;38(10):2845–2854.
   PubMed Web of Science ®Google Scholar
• Mohanakrishnan R, Beier S, Deodhar A. IL-23 inhibition for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2022 Jan;22(1):59–65.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun;73(6):1020–1026.
   PubMed Web of Science ®Google Scholar
• Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev. 2017 Jan;16(1):10–15.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009 Nov;124(5):1022–10.e1–395.
   Web of Science ®Google Scholar
• Chabaud M, Garnero P, Dayer JM, et al. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 2000 Jul;12(7):1092–1099.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777–783.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017 Jun;76(6):978–991.
   PubMed Web of Science ®Google Scholar
• Zhu W, He X, Cheng K, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22.
   PubMed Web of Science ®Google Scholar
• Chen B, Li J, He C, et al. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review). Mol Med Rep. 2017 Apr;15(4):1943–1951.
   PubMed Web of Science ®Google Scholar
• DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009 Sep;60(9):2633–2643.
   PubMed Web of Science ®Google Scholar
• Chan AT, Kollnberger SD, Wedderburn LR, et al. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 2005 Nov;52(11):3586–3595.
   PubMedGoogle Scholar
• York IA, Chang SC, Saric T, et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol. 2002 Dec;3(12):1177–1184.
   PubMed Web of Science ®Google Scholar
• Guiliano DB, Fussell H, Lenart I, et al. Endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 1 targets misfolded HLA-B27 dimers for endoplasmic reticulum-associated degradation. Arthritis Rheumatol. 2014 Nov;66(11):2976–2988.
   PubMed Web of Science ®Google Scholar
• Cortes A, Pulit SL, Leo PJ, et al. Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nat Commun. 2015 May 21;6:7146.
   PubMed Web of Science ®Google Scholar
• Costello ME, Ciccia F, Willner D, et al. Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol. 2015 Mar;67(3):686–691.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017 Jun;76(6):1123–1132.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Bombardieri M, Principato A, et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2009 Apr;60(4):955–965.
   PubMed Web of Science ®Google Scholar
• Jacques P, Lambrecht S, Verheugen E, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis. 2014 Feb;73(2):437–445.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gensler LS, Sieper J, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019 02;71(2):70–258.
   Web of Science ®Google Scholar
• Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018 09;77(9):302–1295.
   Web of Science ®Google Scholar
• Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun. 2018 02;87:1–15.
   PubMed Web of Science ®Google Scholar
• Yeremenko N, Noordenbos T, Cantaert T, et al. Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis. Arthritis Rheum. 2013 Jan;65(1):174–185.
   PubMedGoogle Scholar
• Noack M, Ndongo-Thiam N, Miossec P. Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion. Arthritis Res Ther. 2016 Jun 23;18:148.
   PubMed Web of Science ®Google Scholar
• Noack M, Ndongo-Thiam N, Miossec P. Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells. Clin Exp Immunol. 2016 10;186(1):64–74.
   PubMed Web of Science ®Google Scholar
• Jubair WK, Hendrickson JD, Severs EL, et al. Modulation of inflammatory arthritis in mice by gut microbiota through mucosal inflammation and autoantibody generation. Arthritis Rheumatol. 2018 08; 70(8): 1220–1233.
   PubMed Web of Science ®Google Scholar
• Van Praet L, Jans L, Carron P, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014 Jun;73(6):1186–1189.
   PubMed Web of Science ®Google Scholar
• Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-T. Nat Immunol. 2017 01; 18(1): 104–113.
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Bloch Y, Składanowska K, et al. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: a molecular insight. Clin Immunol. 2019 09;206:15–22.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31 382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014 Jun;73(6):990–999.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014 Jun;73(6):6–1000.
   PubMed Web of Science ®Google Scholar
• Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019 02; 48(4): 632–637.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and crohn’s disease: an integrated analysis of phase ii/iii clinical development programs. Drug Saf. 2019 06; 42(6): 751–768.
   PubMed Web of Science ®Google Scholar
• Li X, Andersen KM, Chang HY, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020 02;79(2):91–285.
   Web of Science ®Google Scholar
• Kawalec P, Holko P, Moćko P, et al. Comparative effectiveness of Abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018 Feb;38(2):189–201.
   PubMed Web of Science ®Google Scholar
• Haddad A, Gazitt T, Feldhamer I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021 Jan 29;23(1):44.
   PubMed Web of Science ®Google Scholar
• Sewerin P, Borchert K, Meise D, et al. Real-World treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis-a retrospective database study. Rheumatol Ther. 2021 Mar;8(1):483–497.
   PubMed Web of Science ®Google Scholar
• Iannone F, Santo L, Bucci R, et al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). Clin Rheumatol. 2018 Mar;37(3):667–675.
   PubMed Web of Science ®Google Scholar
• Geale K, Lindberg I, Paulsson EC, et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020;4(2):rkaa070.
   PubMedGoogle Scholar
• Walsh JA, Cai Q, Lin I, et al. Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin. 2020 07; 36(7): 1245–1252.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ortolan A, Lorenzin M, et al. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study. Clin Rheumatol. 2018 Feb;37(2):397–405.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018 Jun 02;391(10136):24–2213.
   Web of Science ®Google Scholar
• Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 4;395(10230):1115–1125.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020 Apr 04;395(10230):36–1126.
   Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Deodhar A, et al. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open. 2020 07; 6(2): e001217.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthriti. Arthritis Rheumatol. 2021 04;73(4):604–616.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kellner H, Morita A, et al. OP0307 efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann Rheum Dis. 2018;77(Suppl 2):200–201.
   Google Scholar
• Kristensen LE, Keiserman M, Papp K, et al. AB0559 efficacy and safety of risankizumab in patients with active psoriatic arthritis after inadequate response or intolerance to DMARDs: 24-week results from the phase 3, randomized, double-blind keepsake 1 trial. Ann Rheum Dis. 2021;80(Suppl 1):1315–1316.
   Google Scholar
• Ostor A, Van den Bosch F, Papp K, et al. OP0228 Efficacy and safety of risankizumab for active psoriatic arthritis, including patients with inadequate response or intolerance to biologic therapies: 24-week results from the phase 3, randomized, double-blind, keepsake 2 trial. Annals of the Rheumatic Diseases. 2021;80(Suppl 1):9–138.
   Google Scholar
• Ismail FF, May J, Moi J, et al. Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment. Dermatol Ther. 2020 03; 33(2): e13216.
   PubMed Web of Science ®Google Scholar
• Langley RG, Thaçi D, Reich K, et al. FRI0445 tildrakizumab treatment improved measures of psoriatic arthritis in adults with chronic plaque psoriasis. Ann Rheum Dis. 2016;75(Suppl 2):596–597.
   Google Scholar
• Mease PJ, Chohan S, Fructuoso FJG, et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis. 2021 09;80(9):57–1147.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014 May;73(5):817–823.
   PubMed Web of Science ®Google Scholar
• Research J, Development L. A study of guselkumab administered subcutaneously in bio-naive participants with active psoriatic arthritis axial disease (STAR) in: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04929210NLMIdentifier:NCT04929210
   Google Scholar
• Ceribelli A, Motta F, Vecellio M, et al. Clinical trials supporting the role of the IL-17/IL-23 axis in axial spondyloarthritis. Front Immunol. 2021;12:622770.
   PubMed Web of Science ®Google Scholar
• Limited SPI. A randomized, double-blind, placebo-controlled phase 2a study to evaluate the efficacy and safety of tildrakizumab in subjects with active ankylosing spondylitis or non-radiographic axial spondyloarthritis in: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: https://clinicaltrials.gov/ct2/show/study/NCT02980705. NLM Identifier: NCT02980705
   Google Scholar
• Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis. 2016 Nov;75(11):1984–1988.
   PubMed Web of Science ®Google Scholar
• Helliwell PS, Gladman DD, Chakravarty SD, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020 02; 6(1): e001149.
   PubMed Web of Science ®Google Scholar
• Helliwell P, Gladman DD, Poddubnyy D, et al. OP0054 efficacy of guselkumab, a monoclonal antibody that specifically binds to the p19-subunit of IL-23, on endpoints related to axial involvement in patients with active psa with imaging-confirmed sacroiliitis: week-24 results from two phase 3, randomized, double-blind, placebo-controlled studies. Ann Rheum Dis. 2020;79(Suppl 1):36–37.
   Google Scholar
• Braun J, Landewé RB. No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’? Ann Rheum Dis. 2022;81(4):466–468.
   PubMed Web of Science ®Google Scholar
• Baeten D, Adamopoulos IE. IL-23 inhibition in ankylosing spondylitis: where did it go wrong? Front Immunol. 2020;11:623874.
   PubMed Web of Science ®Google Scholar